Picture Berlin Partner Voices Robinson Data for Precision Medicine 650x100px

Product › Details

vidofludimus calcium (IMU-838, Immunic)

	Next higher product group	DHODH inhibitor
	Status	2016-09-28 development pp existent
	Organisation	Immunic AG
	Group	Immunic (Group)
	Organisation 2	4SC AG (FSE: VSC)
	Group	4SC (Group)

Record changed: 2024-01-07

Picture Swiss Biotech Association Swiss Biotech Days 2024 SBD24 Basel 650x200px

More documents for vidofludimus calcium (IMU-838, Immunic)

[1] Immunic, Inc.. (1/5/24). "Press Release: Immunic, Inc. Announces Private Placement of up to $240 Million". New York, NY....
[2] Immunic, Inc.. (11/2/23). "Press Release: Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts". New York, NY....
[3] Immunic, Inc.. (7/6/22). "Press Release: Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Maria Törnsén". New York, NY....
[4] Immunic, Inc.. (6/2/22). "Press Release: Immunic, Inc. Reports Top-Line Data from Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Patients with Moderate-to-Severe Ulcerative Colitis and Provides Corporate Update". New York, NY....
[5] Immunic, Inc.. (3/16/22). "Press Release: Immunic, Inc. Announces Promotion of Glenn Whaley, CPA to Chief Financial Officer". New York, NY....
[6] Immunic, Inc.. (10/14/21). "Press Release: Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer". New York, NY....
[7] Immunic, Inc.. (7/19/21). "Press Release: Immunic, Inc. Announces Closing of $45.0 Million Public Offering". New York, NY....
[8] Immunic, Inc.. (3/31/21). "Press Release: Immunic and 4SC AG Sign Agreement Regarding the Settlement of Royalty Obligations for Immunic’s Lead Program, IMU-838". New York, NY & Planegg-Martinsried....
[9] Immunic, Inc.. (2/26/21). "Press Release: Immunic, Inc. Reports Year End 2020 Financial Results and Highlights Recent Activity". New York, NY....
[10] Immunic, Inc.. (12/14/20). "Press Release: Immunic, Inc. Added to NASDAQ Biotechnology Index". New York, NY....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]